Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

0 brokerages have issued 12-month target prices for Paratek Pharmaceuticals' stock. Their PRTK share price forecasts range from $10.00 to $30.00. On average, they anticipate the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 972.4% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.

Paratek Pharmaceuticals' stock was trading at $1.87 at the start of the year. Since then, PRTK shares have decreased by 0.3% and is now trading at $1.8650.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PRTK earnings forecast.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analyst estimates of $22.98 million. During the same quarter in the prior year, the company posted ($0.46) earnings per share.

ETFs with the largest weight of Paratek Pharmaceuticals (NASDAQ:PRTK) stock in their portfolio include AltShares Event-Driven ET (EVNT) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

Paratek Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $143.00 million-$158.00 million, compared to the consensus revenue estimate of $232.02 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (7.48%), General American Investors Co. Inc. (3.39%), Millennium Management LLC (1.02%), Geode Capital Management LLC (0.84%), CM Management LLC (0.62%) and Renaissance Technologies LLC (0.44%). Insiders that own company stock include Adam Woodrow, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends.

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTK stock can currently be purchased for approximately $1.87.

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $106.79 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The company employs 207 workers across the globe.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.